Leveraging the Findings From First in-Human GSI-plus-BCMA Clinical Trial to Understand Mechanisms of Resistance & Optimize Efficacy
Time: 11:30 am
day: Day One
Details:
- Exploring why mechanisms of resistance to BCMA targeted therapies require further elucidation
- Understanding the impact of BCMA antigen density on response, needing to be further characterized
- Discussing why the approach to sequencing BCMA targeting agents may require careful consideration
